AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Regulation FD Disclosure

AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Regulation FD Disclosure
ITEM 7.01 REGULATION FD DISCLOSURE.

Story continues below

Today, at 3:00 PM, New York time, James Joyce, CEO, of Aethlon Medical, Inc. will be making a presentation at the 2017 Rodman & Renshaw 19th Annual Global Investment Conference. A copy of the presentation is attached hereto as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) EXHIBITS


AETHLON MEDICAL INC Exhibit
EX-99.1 2 aethlon_8k-ex9901.htm PRESS RELEASE Exhibit 99.1   Image of Ebola viruses exiting host cells – Courtesy of NIAID 1     The following presentation may contain predictions,…
To view the full exhibit click here

About AETHLON MEDICAL, INC. (NASDAQ:AEMD)

Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

An ad to help with our costs